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Abstract Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing. Triptans • Indications   S89 are better tolerated when the patient is nauseous. The spray is somewhat faster acting than the tablets, while the injections are the fastest acting of any of the formulations.
Key words
-Zolmitriptan is supplied in tablet and melt forms. It is generally well tolerated and is considered as effective as sumatriptan. -Naratriptan is supplied only in tablet form.
-Rizatriptan is available in two types of tablets and in two types of melt. -Almotriptan, the newest of the triptans currently available, is available in a 12.5-mg tablet.
Results
Among the eight countries considered, notable differences exist regarding the availability of the 5 major triptans and their pharmaceutical forms ( Table 1 ). All four sumatriptan formulations (tablets, injection, spray and suppositories) are available in Italy and Germany. Tablets and injection are available in the UK, injection and spray in France, spray and suppositories in Sweden, and tablets, injection and spray in both the US and Canada. Sumatriptan tablets (25 mg) are available in the US only, 100-mg tablets are available in Italy, Germany and Canada, and 50-mg tablets are available in all countries investigated. The pack size for the 50-mg tablet ranges from 2 to 24 units in the UK, while it contains 4 units in Italy, 6 units in Germany and 9 units in the US and Canada.
Naratriptan is available in tablets of 1 mg only in the US, whereas the 2.5-mg form is available in the UK, Sweden and Germany. Zolmitriptan is obtainable in 2.5 and 5 mg tablets and melts. Rizatriptan is available in tablets and melts of 5 and 10 mg whereas almotriptan it is only available in 12.5-mg tablets in the UK. The differences in triptan availability for the eight countries are also reflected in the licensed dosages (Table 2) . For sumatriptan spray, in most of the European countries the approved attack dosage is 20 mg whereas in France the licensed attack dosage is 10 mg, the same as in the US and Canada. The maximal daily dosage is 40 mg in all countries investigated, including France, US and Canada.
For the oral form, the maximal daily dosage is 200 mg in all eight countries. The attack dose is 50 mg in all European countries, while it is 25 mg in the US and Canada. For the injection formulation, the minimum and maximum licensed posologies are 6 and 12 mg, respectively.
The attack dose for naratriptan is 2.5 mg in European countries while it is 1 mg in the US.
The attack dose for zolmitriptan is 2.5 mg in all European countries while it is 1.25 mg in the US. The maximal daily dose is 10 mg in the US and in all the European countries but the UK (where it is 15 mg). For rizatriptan, the attack dose is 5 mg in US (half of the European dosage), but the maximal daily dosage is 30 mg as compared with 20 mg in European countries. Finally, almotriptan is available in 12.5-mg tablets (minimum) and 25-mg tablets (maximum) in the UK.
Discussion
There are differences between the different countries in the presentations of triptans and in their licensed indications and dosages. The differences between European countries and US and Canada are not always in the same directions and thus a more important role of the scientific community is necessary in better harmonizing the utilization of this important therapeutic class. 
